{"id":1309,"date":"2026-11-17T15:00:53","date_gmt":"2026-11-17T15:00:53","guid":{"rendered":"https:\/\/snap-trove.co.za\/?p=1309"},"modified":"2026-11-17T15:00:53","modified_gmt":"2026-11-17T15:00:53","slug":"the-alzheimers-paradox-early-diagnosis-is-here-effective-treatment-isnt","status":"publish","type":"post","link":"https:\/\/snap-trove.co.za\/index.php\/2026\/11\/17\/the-alzheimers-paradox-early-diagnosis-is-here-effective-treatment-isnt\/","title":{"rendered":"The Alzheimer&#8217;s Paradox: Early Diagnosis Is Here. Effective Treatment Isn&#8217;t"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">In 2026, a blood test can detect biological signs of Alzheimer&#8217;s disease years before memory problems become apparent. The same test can help determine who qualifies for the first drugs capable of slowing the disease. Researchers can now track the proteins responsible for damaging the brain, identify people at elevated risk, and intervene while patients are still functioning independently. Yet there is no cure. The benefits of existing treatments remain modest, their risks are significant, and scientists are increasingly questioning whether Alzheimer&#8217;s should even be understood as a single disease.<\/span><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-1311\" src=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/alzheimers-desease-300x215.jpg\" alt=\"\" width=\"300\" height=\"215\" srcset=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/alzheimers-desease-300x215.jpg 300w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/alzheimers-desease-768x550.jpg 768w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/alzheimers-desease.jpg 967w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p><!--nextpage--><\/p>\n<h2><span style=\"font-weight: 400;\">The first drugs that change the disease<\/span><\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-1313\" src=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/medication-300x205.jpg\" alt=\"\" width=\"300\" height=\"205\" srcset=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/medication-300x205.jpg 300w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/medication-768x526.jpg 768w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/medication.jpg 967w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p><span style=\"font-weight: 400;\">For decades, Alzheimer&#8217;s treatments focused on managing symptoms. Medications such as donepezil could temporarily improve memory and cognitive function, but they did little to address the underlying biological processes destroying brain cells. That began to change with the arrival of lecanemab and donanemab, two monoclonal antibody drugs designed to remove amyloid-beta plaques from the brain. These protein deposits are one of the defining features of Alzheimer&#8217;s pathology and have been a central target of research for decades.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Both drugs demonstrated an ability to slow cognitive decline in large Phase 3 clinical trials. Lecanemab reduced the rate of decline by 27% over 18 months compared with placebo. Donanemab also produced significant results, with approximately 22\u201335% slowing depending on the patient group and cognitive measure used. In practical terms, researchers have estimated the difference as several months of delayed progression over the treatment period.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">These are genuine disease-modifying treatments: they intervene in the biological mechanisms of Alzheimer&#8217;s rather than simply treating its symptoms. But their limitations are substantial. Both drugs are intended for patients in the early stages of the disease, before extensive neurological damage has occurred. They also carry the risk of amyloid-related imaging abnormalities (ARIA), which can cause brain swelling and microbleeds, sometimes with serious consequences. Treatment requires regular infusions, repeated MRI scans, and careful medical supervision.<\/span><\/p>\n<p><!--nextpage--><\/p>\n<h2><span style=\"font-weight: 400;\">A blood test can see what the patient cannot<\/span><\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-1312\" src=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/alzheimers-prediction-300x205.jpg\" alt=\"\" width=\"300\" height=\"205\" srcset=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/alzheimers-prediction-300x205.jpg 300w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/alzheimers-prediction-768x526.jpg 768w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/alzheimers-prediction.jpg 967w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p><span style=\"font-weight: 400;\">One of the most significant developments in Alzheimer&#8217;s research is happening in diagnostic laboratories. The plasma p-tau217 test measures phosphorylated tau, a protein associated with the pathological processes of Alzheimer&#8217;s. Studies have reported diagnostic performance approaching 96% in identifying amyloid pathology, with results comparable to established imaging and cerebrospinal fluid methods.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">In May 2026, Roche received CE marking for its Elecsys pTau217 blood test, designed to identify or rule out amyloid pathology using a routine blood sample. In August, the test also received FDA clearance in the United States for patients aged 55 and older presenting with signs or symptoms of cognitive decline. This brings a sophisticated neurological biomarker much closer to ordinary clinical practice.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The implications are enormous. Alzheimer&#8217;s pathology can begin accumulating 15\u201320 years before recognizable symptoms appear. Researchers are developing increasingly sensitive tools to identify this process long before someone starts struggling with familiar names, conversations, or everyday tasks. Blood tests are also part of a broader diagnostic revolution. Researchers are investigating AI-assisted retinal imaging to identify neurological changes through routine eye examinations, alongside digital smell tests that measure early olfactory dysfunction. The objective is to make detection faster, cheaper, and accessible outside specialist memory clinics.<\/span><\/p>\n<p><!--nextpage--><\/p>\n<h2><span style=\"font-weight: 400;\">Tau: the next major target<\/span><\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-1314\" src=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/Tau-300x205.jpg\" alt=\"\" width=\"300\" height=\"205\" srcset=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/Tau-300x205.jpg 300w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/Tau-768x526.jpg 768w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/Tau.jpg 967w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p><span style=\"font-weight: 400;\">Amyloid plaques have dominated Alzheimer&#8217;s research, but another protein may be even more closely connected to the symptoms patients experience. Tau normally helps stabilize the internal structure of neurons. In Alzheimer&#8217;s, abnormal tau proteins accumulate into tangled structures that interfere with cellular function and contribute to neuronal death.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">A major development came from research on the experimental therapy BIIB080, also known as diranersen. The drug uses antisense oligonucleotides to reduce production of tau protein. Exploratory PET imaging analyses reported reductions in aggregated tau across multiple brain regions following prolonged treatment. It was the first reported observation of this kind in response to a disease-modifying therapy. Detailed Phase 2 results presented in July 2026 provided further evidence that tau-targeting approaches could become an important part of future treatment strategies. The findings offer a potential alternative to the amyloid-centered approach that has dominated the field.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Other experimental approaches include anti-tau antibodies designed to interfere with the spread of abnormal proteins between neurons. Researchers are increasingly interested in targeting several pathological mechanisms simultaneously.<\/span><\/p>\n<p><!--nextpage--><\/p>\n<h2><span style=\"font-weight: 400;\">The brain&#8217;s immune system enters the picture<\/span><\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-1315\" src=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/TREM-2-300x205.jpg\" alt=\"\" width=\"300\" height=\"205\" srcset=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/TREM-2-300x205.jpg 300w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/TREM-2-768x526.jpg 768w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/TREM-2.jpg 967w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p><span style=\"font-weight: 400;\">Another emerging research direction concerns TREM2, a receptor involved in regulating microglia: the brain&#8217;s resident immune cells. These cells help remove cellular debris and respond to damage, including the accumulation of abnormal proteins.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Researchers have investigated whether stimulating TREM2 could improve the brain&#8217;s ability to manage Alzheimer&#8217;s pathology. One experimental antibody, AL002, was developed specifically for this purpose. However, its Phase 2 trial failed to demonstrate a significant clinical benefit, despite showing biological activity. The results illustrate how difficult it remains to translate promising mechanisms into effective treatments.<\/span><\/p>\n<p><!--nextpage--><\/p>\n<h2><span style=\"font-weight: 400;\">Is Alzheimer&#8217;s actually one disease?<\/span><\/h2>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-1310\" src=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/alzheimers-desease-2-300x205.jpg\" alt=\"\" width=\"300\" height=\"205\" srcset=\"https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/alzheimers-desease-2-300x205.jpg 300w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/alzheimers-desease-2-768x526.jpg 768w, https:\/\/snap-trove.co.za\/wp-content\/uploads\/2026\/11\/alzheimers-desease-2.jpg 967w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/p>\n<p><span style=\"font-weight: 400;\">Perhaps the biggest challenge facing researchers is the growing recognition of Alzheimer&#8217;s biological complexity. Patients can develop different patterns of neurological damage, experience different symptoms, and deteriorate at dramatically different rates. Some experience memory impairment first; others develop language difficulties, visual disturbances, or changes in executive function. Genetic factors, vascular damage, immune responses, and other protein abnormalities can all influence the disease.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Research increasingly points toward distinct molecular subtypes with different biological characteristics and trajectories. This has significant consequences for treatment development. A drug targeting amyloid may help one group of patients while leaving other important mechanisms untouched. Future therapies may need to be tailored to individual biological profiles, potentially combining several treatments rather than relying on a single target.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Alzheimer&#8217;s research has entered an entirely new era. Scientists can increasingly identify the disease before its symptoms emerge, measure its underlying pathology, and intervene in mechanisms that were previously inaccessible. Yet the distance between detecting a disease and knowing how to stop it remains enormous. In 2026, medicine can see Alzheimer&#8217;s coming. It still cannot reliably prevent it from arriving.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In 2026, a blood test can detect biological signs of Alzheimer&#8217;s disease years before memory problems become apparent. The same test can help determine who qualifies for the first drugs&#8230;<\/p>\n","protected":false},"author":1,"featured_media":1312,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2,10,6],"tags":[],"class_list":["post-1309","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-exclusives","category-psychology","category-science"],"_links":{"self":[{"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/posts\/1309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/comments?post=1309"}],"version-history":[{"count":1,"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/posts\/1309\/revisions"}],"predecessor-version":[{"id":1316,"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/posts\/1309\/revisions\/1316"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/media\/1312"}],"wp:attachment":[{"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/media?parent=1309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/categories?post=1309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/snap-trove.co.za\/index.php\/wp-json\/wp\/v2\/tags?post=1309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}